Key Takeaways:
Pharming Group shares fell 22% on July 31 after the biotech reported a 10% year-over-year decline in second-quarter sales of its legacy product RUCONEST.
Levi & Korsinsky, a shareholder-rights law firm, said it is investigating potential securities law violations on behalf of Pharming shareholders, according to a notice the firm issued after the drop. The firm typically pursues claims that a company made misleading statements about its business or financial condition, and its probe could lead to a shareholder lawsuit if evidence of wrongdoing emerges.
RUCONEST, the brand name for conestat alfa, a recombinant human C1 esterase inhibitor used to treat hereditary angioedema, has long been Pharming's core revenue driver. Hereditary angioedema is a rare genetic disorder marked by recurrent episodes of severe swelling, and RUCONEST has been a mainstay of acute treatment since its approval. The 10% sales decline in the second quarter of 2026 marks a sharp deterioration in the product's trajectory as the company shifts toward newer therapies for growth.
The hereditary angioedema market has grown more competitive, with newer prophylactic options from Takeda and BioCryst Pharmaceuticals eroding demand for older acute therapies. RUCONEST faces pressure from these rivals as patients shift toward preventive treatment, a trend that may explain part of the second-quarter decline.
The single-day plunge erased a substantial portion of Pharming's market value and leaves the company more dependent on its pipeline, including Joenja (leniolisib), its treatment for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency. The pending investigation could expose the company to additional shareholder litigation and regulatory scrutiny, adding pressure on a stock already trading near multi-year lows.
For shareholders, the combination of falling legacy sales and a securities probe raises questions about Pharming's ability to fund its development programs. RUCONEST has historically provided the cash flow that underwrites the company's research spending, and a sustained decline in that revenue stream could force management to prioritize or delay pipeline investments.
The decline shows Pharming's transition away from RUCONEST is proving slower than investors expected, and the investigation adds a legal overhang. Shareholders will watch for any update from the law firm and for the company's next earnings call to gauge pipeline revenue growth, which will clarify whether the RUCONEST decline is a one-quarter blip or a structural trend.
This article is for informational purposes only and does not constitute investment advice.
